Literature DB >> 15477531

A focus on the synapse for neuroprotection in Alzheimer disease and other dementias.

Paul Coleman1, Howard Federoff, Roger Kurlan.   

Abstract

Synaptic dysfunction and failure are processes that occur early in Alzheimer disease (AD) and are important targets for protective treatments to slow AD progression and preserve cognitive and functional abilities. Synaptic loss is the best current pathologic correlate of cognitive decline, and synaptic dysfunction is evident long before synapses and neurons are lost. Once synaptic function fails, even in the setting of surviving neurons, there may be little chance of effectively interfering with the disease process. This review emphasizes the importance of preserving synaptic structure and function (i.e., "synaptoprotection") in AD. Such "synaptoprotective" therapy will probably need to be administered at a critical early time point, perhaps years before onset of clinical symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15477531     DOI: 10.1212/01.wnl.0000140626.48118.0a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  103 in total

1.  The Achilles heel of γ-secretase: can we contain Alzheimer's disease by reducing synthesis of β-amyloid?

Authors:  Alexei Verkhratsky; José Julio Rodríguez
Journal:  Acta Pharmacol Sin       Date:  2010-10-11       Impact factor: 6.150

2.  7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease.

Authors:  Zhentao Zhang; Xia Liu; Jason P Schroeder; Chi-Bun Chan; Mingke Song; Shan Ping Yu; David Weinshenker; Keqiang Ye
Journal:  Neuropsychopharmacology       Date:  2013-09-11       Impact factor: 7.853

3.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 4.  Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease.

Authors:  Xiongwei Zhu; George Perry; Mark A Smith; Xinglong Wang
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases.

Authors:  Ben A Bahr; Meagan L Wisniewski; David Butler
Journal:  Rejuvenation Res       Date:  2012-04       Impact factor: 4.663

6.  Dietary restriction enhances kainate-induced increase in NCAM while blocking the glial activation in adult rat brain.

Authors:  Sandeep Sharma; Gurcharan Kaur
Journal:  Neurochem Res       Date:  2007-11-10       Impact factor: 3.996

7.  Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway.

Authors:  Shang-Yi Tsai; Teruo Hayashi; Brandon K Harvey; Yun Wang; Wells W Wu; Rong-Fong Shen; Yongqing Zhang; Kevin G Becker; Barry J Hoffer; Tsung-Ping Su
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

8.  Impaired balance of mitochondrial fission and fusion in Alzheimer's disease.

Authors:  Xinglong Wang; Bo Su; Hyoung-gon Lee; Xinyi Li; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

9.  Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala-diazomethylketone.

Authors:  Sophia Ryzhikov; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2007-09-18       Impact factor: 3.444

Review 10.  Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies.

Authors:  Bradford C Dickerson; Reisa A Sperling
Journal:  Neuropsychologia       Date:  2007-12-08       Impact factor: 3.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.